Current Psychiatry Reports

, Volume 11, Issue 5, pp 360–363

Treatment of opioid-dependent adolescents and young adults with buprenorphine

  • Geetha A. Subramaniam
  • Marc J. Fishman
  • George Woody
Article

DOI: 10.1007/s11920-009-0054-5

Cite this article as:
Subramaniam, G.A., Fishman, M.J. & Woody, G. Curr Psychiatry Rep (2009) 11: 360. doi:10.1007/s11920-009-0054-5

Abstract

Rising rates of opioid use among teenagers and young adults are a public health concern. Despite short durations of opioid use compared with those of adults, youth with opioid dependence have a host of co-occurring conditions, including polysubstance abuse, psychiatric disorders, hepatitis C infection, HIV risk, and high-risk sexual and criminal behaviors. Opioid-dependent youth typically are offered outpatient/residential treatment with brief detoxification, but one study showed that heroin users fare worse following residential treatment. Although abundant research supports the use of medication-assisted treatment for opioid-dependent adults, research is only recently emerging for youth. Buprenorphine, a partial opioid agonist, was proven safe and effective in improving abstinence from opioids in two controlled clinical trials. More research is needed to determine several clinically relevant areas: appropriate duration of agonist treatment, ways to enhance medication adherence, the value of integrated treatments for co-occurring conditions, and the role of opioid antagonists in opioid-dependent youth.

Copyright information

© Current Medicine Group, LLC 2009

Authors and Affiliations

  • Geetha A. Subramaniam
    • 1
  • Marc J. Fishman
  • George Woody
  1. 1.Department of PsychiatryJohns Hopkins UniversityBaltimoreUSA